A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Ewing's sarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors ARIAD Pharmaceuticals; Merck Sharp & Dohme
- 23 Jan 2013 Primary endpoint added as reported by ClinicalTrials.gov.
- 06 Oct 2009 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov.
- 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.